Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Clinical Efficacy and Safety of DiaPep277 in Newly Diagnosed Type 1 Diabetes Subjects

NCT01103284 is registered in ClinicalTrials.gov with Andromeda Biotech Ltd. as lead sponsor.

NCT NCT01103284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01103284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Clinical Efficacy and Safety of DiaPep277 in Newly Diagnosed Type 1 Diabetes Subjects
Lead sponsor
Andromeda Biotech Ltd.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2010
Completion date
October 31, 2014
Enrollment
475 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus